Research progress on risk factors of de novo malignancy after liver transplantation

Meng Lingzhan; Liu Zhenwen; Zhu Zhenyu

doi:10.3969/j.issn.1674-7445.2020.05.019

Volume 11 Issue 5

Sep. 2020

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2020 > 11(5): 646-650

Meng Lingzhan, Liu Zhenwen, Zhu Zhenyu. Research progress on risk factors of de novo malignancy after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(5): 646-650. doi: 10.3969/j.issn.1674-7445.2020.05.019

Citation:

PDF( 846 KB)

Research progress on risk factors of de novo malignancy after liver transplantation

doi: 10.3969/j.issn.1674-7445.2020.05.019

Department of Hepatobiliary Surgery, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

More Information

Corresponding author: Zhu Zhenyu, Email: zhuzy302@163.com
Received Date: 2020-06-10
Available Online: 2021-01-19
Publish Date: 2020-09-15

Abstract

Abstract

De novo malignancy after liver transplantation is an important factor that affecting the long-term survival of recipient. The main risk factors for de novo malignancy include immunosuppression and many factors of recipients, such as age, gender, race, primary disease, preoperative tumor history and precancerous lesion, carcinogenic virus infection, smoking and drinking, etc. Currently, there is no standardized monitoring scheme after liver transplantation, but planned monitoring is required for high-risk recipients, thus to achieve early diagnosis and improve the survival rate. This article summarized the incidence, prognosis and related risk factors of de novo malignancy after liver transplantation, which provided reference for improving long-term survival rate of recipients after liver transplantation.
- Liver transplantation,
- De novo malignancy,
- Immunosuppression,
- Mammalian target of rapamycin (mTOR) inhibitor,
- Hepatocellular carcinoma,
- Virus infection,
- Precancerous lesion,
- Smoking-related malignancy

FullText(HTML)

References(30)

References

[1]	CHATRATH H, BERMAN K, VUPPALANCHI R, et al. De novo malignancy post-liver transplantation: a single center, population controlled study[J]. Clin Transplant, 2013, 27(4):582-590. DOI: 10.1111/ctr.12171.
[2]	ZHOU J, HU Z, ZHANG Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database[J]. PLoS One, 2016, 11(5):e0155179. DOI:10.1371/journal. pone.0155179.
[3]	PARK HW, HWANG S, AHN CS, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry[J]. Transplant Proc, 2012, 44(3):802- 805. DOI: 10.1016/j.transproceed.2012.01.027.
[4]	AGUIAR D, MARTÍNEZ-URBISTONDO D, D'AVOLA D, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation[J]. Ann Transplant, 2017, 22:141- 147. DOI: 10.12659/aot.901556.
[5]	RADEMACHER S, SEEHOFER D, EURICH D, et al. The 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients[J]. Liver Transpl, 2017, 23(11):1404-1414. DOI: 10.1002/lt.24795.
[6]	NORDIN A, ÅBERG F, PUKKALA E, et al. Decreasing incidence of cancer after liver transplantation-a Nordic population-based study over 3 decades[J]. Am J Transplant, 2018, 18(4):952-963. DOI: 10.1111/ajt.14507.
[7]	BHAT M, MARA K, DIERKHISING R, et al. Gender, race and disease etiology predict de novo malignancy risk after liver transplantation: insights for future individualized cancer screening guidance[J]. Transplantation, 2019, 103(1): 91-100. DOI: 10.1097/TP.0000000000002113.
[8]	SHERSTON SN, CARROLL RP, HARDEN PN, et al. Predictors of cancer risk in the long-term solid-organ transplant recipient[J]. Transplantation, 2014, 97(6):605- 611. DOI: 10.1097/01.TP.0000436907.56425.5c.
[9]	JIMÉNEZ-ROMERO C, JUSTO-ALONSO I, CAMBRAMOLERO F, et al. Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis[J]. World J Hepatol, 2015, 7(7):942- 953. DOI: 10.4254/wjh.v7.i7.942.
[10]	TJON AS, SINT NICOLAAS J, KWEKKEBOOM J, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C₂ monitoring and recipient age[J]. Liver Transpl, 2010, 16(7):837-846. DOI: 10.1002/lt.22064.
[11]	WIMMER CD, ANGELE MK, SCHWARZ B, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients[J]. Transpl Int, 2013, 26(10):999-1006. DOI: 10.1111/tri.12165.
[12]	CARENCO C, ASSENAT E, FAURE S, et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship[J]. Am J Transplant, 2015, 15(3):678- 686. DOI: 10.1111/ajt.13018.
[13]	RODRÍGUEZ-PERÁLVAREZ M, GERMANI G, DARIUS T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and Meta-analysis[J]. Am J Transplant, 2012, 12(10):2797-2814. DOI: 10.1111/j.1600-6143.2012.04140.x.
[14]	CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10):1039-1049. DOI: 10.1111/tri.12372.
[15]	THIMONIER E, GUILLAUD O, WALTER T, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease[J]. Clin Transplant, 2014, 28(12): 1339-1348. DOI: 10.1111/ctr.12430.
[16]	HERRERO JI, LUCENA JF, QUIROGA J, et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy[J]. Am J Transplant, 2003, 3(11):1407-1412. DOI:10.1046/j.1600- 6143.2003.00227.x.
[17]	SÉRÉE O, ALTIERI M, GUILLAUME E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11, 226 patients[J]. Liver Transpl, 2018, 24(10):1425-1436. DOI: 10.1002/lt.25310.
[18]	TANAKA T, VOIGT MD. Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation[J]. J Cancer Res Clin Oncol, 2018, 144(3):607-615. DOI:10.1007/s00432-018- 2589-5.
[19]	姜晓青, 张群, 解曼, 等.中国肝移植术后新发消化系统恶性肿瘤文献分析报告[J].器官移植, 2020, 11(2): 265-270. DOI: 10.3969/j.issn.1674-7445.2020.02.013. JIANG XQ, ZHANG Q, XIE M, et al. Literature analysis report of de novo malignant tumors of digestive system after liver transplantation in China[J]. Organ Transplant, 2020, 11(2): 265-270. DOI: 10.3969/j.issn.1674-7445. 2020.02.013.
[20]	WATT KD, PEDERSEN RA, KREMERS WK, et al. Long-term probability of and mortality from de novo malignancy after liver transplantation[J]. Gastroenterology, 2009, 137(6):2010-2017. DOI: 10.1053/j.gastro.2009.08.070.
[21]	SANNA C, ROSSO C, MARIETTI M, et al. Non-alcoholic fatty liver disease and extra-hepatic cancers[J]. Int J Mol Sci, 2016, 17(5):717. DOI: 10.3390/ijms17050717.
[22]	PARK GC, HWANG S, AHN CS, et al. Pretransplant hepatic malignancy increases risk of de novo malignancy after liver transplantation[J]. J Korean Med Sci, 2020, 35(11):e69. DOI: 10.3346/jkms.2020.35.e69.
[23]	MENACHEM Y, SAFADI R, ASHUR Y, et al. Malignancy after liver transplantation in patients with premalignant conditions[J]. J Clin Gastroenterol, 2003, 36(5):436-439. DOI: 10.1097/00004836-200305000-00016.
[24]	OEZCELIK A, KAISER GM, DECHÊNE A, et al. Progression to adenocarcinoma in Barrett's esophagus after liver transplantation[J]. Transplantation, 2011, 91(11):1250- 1253. DOI: 10.1097/TP.0b013e31821841a0.
[25]	PISELLI P, BUSNACH G, FRATINO L, et al. De novo malignancies after organ transplantation: focus on viral infections[J]. Curr Mol Med, 2013, 13(7):1217-1227. DOI: 10.2174/15665240113139990041.
[26]	TABORELLI M, PISELLI P, ETTORRE GM, et al. Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014[J]. Int J Cancer, 2018, 143(7):1588-1594. DOI: 10.1002/ijc.31552.
[27]	TREVISANI F, GARUTI F, CUCCHETTI A, et al. De novo hepatocellular carcinoma of liver allograft: a neglected issue[J]. Cancer Lett, 2015, 357(1):47-54. DOI: 10.1016/j.canlet.2014.11.032.
[28]	MANGUS RS, FRIDELL JA, KUBAL CA, et al. Worse long-term patient survival and higher cancer rates in liver transplant recipients with a history of smoking[J]. Transplantation, 2015, 99(9):1862-1868. DOI:10.1097/ TP.0000000000000671.
[29]	HERRERO JI, PARDO F, D'AVOLA D, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal[J]. Liver Transpl, 2011, 17(4):402-408. DOI: 10.1002/lt.22247.
[30]	BHAT M, MARA K, DIERKHISING R, et al. Immunosuppression, race, and donor-related risk factors affect de novo cancer incidence across solid organ transplant recipients[J]. Mayo Clin Proc, 2018, 93(9):1236- 1246. DOI: 10.1016/j.mayocp.2018.04.025.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (177) PDF downloads(29)

Research progress on risk factors of de novo malignancy after liver transplantation

doi: 10.3969/j.issn.1674-7445.2020.05.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research progress on risk factors of de novo malignancy after liver transplantation

doi: 10.3969/j.issn.1674-7445.2020.05.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content